ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary

Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s first-line non-small cell lung cancer data for its Summit Therapeutics | With honor comes scrutiny. Ivonescimab's plenary status means its Harmoni-6 results in first-line non-small cell lung cancer will be put under the microscope and critiqued carefully at the upcoming ASCO 2026 annual meeting.

Raccontata damorningstar.comfiercepharma.com